Please assess the completion status of the following clinical trial:

Trial Title: Rapid Pleurodesis Through an Indwelling Pleural Catheter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of MPE as defined by~   1. A diagnosis a pleural effusion in the setting of known malignancy. AND~  2. Confirmed malignant involvement of the pleural space by fluid cytology or pleural biopsy. OR~  3. Evidence of pleural disease on radiographic imaging. OR~  4. A recurrent effusion with no other identifiable cause after thorough workup.~2. Symptomatic from the pleural effusions (shortness of breath, cough, or chest pain)~3. Prior thoracentesis with post procedure symptomatic relief~4. Recurrence of symptoms with re-accumulation of pleural effusion~5. Lung re-expansion after thoracentesis on chest imaging within last 30 days~Exclusion Criteria:~1. Malignant pleural effusion due to a hematologic malignancy~2. ECOG \>4~3. Any history of trapped lung~4. Prior attempted pleurodesis on the affected site~5. Age \<18~6. Pregnant or lactating~7. Known allergy to iodopovidone (Betadine)~8. Unable or unwilling to provide consent~9. Uncorrectable coagulopathy (INR \> 1.5, aPTT \> 1.5 x the upper limit of normal) or thrombocytopenia (\< 50,000)~10. Anatomic contraindication to IPC (overlying skin abnormalities)~11. Unable or unwilling to care for IPC and adhere to drainage protocol~12. Need for bilateral IPC placement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: PLACEBO_COMPARATOR): Subjects in this arm will receive placebo only (100mL of normal saline) into the pleural space delivered via the newly placed tunneled intrapleural catheter
- Rapid pleurodesis protocol (Type: EXPERIMENTAL): Subjects in this arm will receive the chemical pleurodesing agent of 10% iodopovidone solution delivered to the pleural space via the newly placed tunneled intrapleural catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).